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Abstract 33 
Background. Three years treatment with either sublingual or subcutaneous allergen 34 
immunotherapy has been shown to be effective and to induce long-term tolerance. The GRASS* 35 
trial demonstrated that two years treatment via either route was effective in suppressing the 36 
response to nasal allergen challenge, although was insufficient for inhibition one year after 37 
discontinuation. 38 
Objective. To examine in the GRASS trial the time-course of immunologic changes during two 39 
years sublingual and subcutaneous immunotherapy and for one year after treatment 40 
discontinuation. 41 
Methods. We performed multi-modal immunomonitoring to assess allergen-specific CD4 T cell 42 
properties, in parallel with analysis of local mucosal cytokine responses induced by nasal 43 
allergen exposure and humoral immune responses that included IgE-dependent basophil 44 
activation and measurement of serum inhibitory activity for allergen-IgE binding to B cells (IgE-45 
Facilitated Allergen Binding).  46 
Results. All three of these distinct arms of the immune response displayed significant and 47 
coordinate alterations during 2 years allergen desensitization, followed by reversal at 3 years, 48 
reflecting a lack of a durable immunological effect. Whereas frequencies of antigen-specific Th2 49 
cells in peripheral blood determined by HLA class II tetramer analysis most closely paralleled 50 
clinical outcomes, IgE-antibody dependent functional assays remained partially inhibited one 51 
year following discontinuation. 52 
Conclusion. Two years of allergen immunotherapy were effective but insufficient for long-term 53 
tolerance. Allergen-specific Th2 cells most closely paralleled the transient clinical outcome and 54 
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it is likely that recurrence of the T cell ‘drivers’ of allergic immunity abrogated the potential for 55 
durable tolerance. On the other hand, persistence of IgE-blocking antibody one year after 56 
discontinuation may be an early indicator of a pro-tolerogenic mechanism. 57 
* Gauging Response in Allergic rhinitis to Sublingual and Subcutaneous immunotherapy 58 
  59 
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Key Messages:  60 
• Two years of grass pollen immunotherapy leads to decreased frequency of circulating 61 
allergen-specific Th2 cells, suppressed increases in nasal cytokine response to allergen 62 
challenge and decreased antigen-specific IgE activity.  63 
Capsule Summary: During and after grass pollen immunotherapy, changes in peripheral 64 
antigen-specific Th2 cells paralleled clinical outcomes, reflecting distinctive cellular response in 65 
concert with changes in specific IgE antibodies and local tissue cytokines, suggesting 66 
coordinated immune mechanisms. 67 
Keywords: Allergy; Immunotherapy; Immune tolerance; Allergen desensitization; Th2 cells 68 
  69 
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Introduction 70 
Allergen immunotherapy is an effective treatment option for patients with allergic rhinitis 71 
who do not respond adequately to usual anti-histamine and topical corticosteroid medications 72 
(1). Subcutaneous immunotherapy involves weekly administration of incremental doses of 73 
allergenic material by injection followed by monthly maintenance injections for several years (2-74 
4). Immunotherapy has been associated with overall changes in T cell function with cytokine 75 
changes that suggest a shift from Th2 cells towards Th1 phenotypes or induction of regulatory T 76 
cells (5, 6). These alterations are accompanied by decreases in recruitment and/or activation of 77 
allergic effector cells including mast cells, eosinophils and basophils in target organs (7, 8). 78 
Measurement of serum immunoglobulins directed against the allergen in such immunotherapy 79 
studies indicates that specific IgG, particularly of the IgG4 subclass, can be induced by therapy 80 
and is presumed to be mechanistically linked to clinical benefit by virtue of competitive 81 
inhibition of allergic responses triggered by specific IgE directed to the same allergens (9-12). 82 
Alternative routes of allergen administration for immunotherapy are now under active 83 
investigation, including sublingual (13-15), and epicutaneous routes (16, 17). For food allergens, 84 
the oral route has also shown promising results (18, 19). Since immunological properties at each 85 
of these sites differ, the mechanisms through which these forms of allergen immunotherapy exert 86 
their therapeutic effects may differ, as well.   87 
The GRASS (Long-Term Effects of Sublingual Grass Therapy) clinical trial was a 88 
randomized, placebo-controlled, double-blind study of 106 adults with a clinical history of 89 
moderate to severe seasonal allergic rhinitis due to grass pollen. Study participants received two 90 
years of subcutaneous immunotherapy, sublingual immunotherapy or placebo and were 91 
extensively studied over three years for clinical and immunological parameters of response (20). 92 
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Clinical assessments in this trial were recently reported, demonstrating successful suppression of 93 
the nasal response to allergen challenge after two years of therapy for both the subcutaneous and 94 
sublingual routes, with lack of sustained benefit in the subsequent untreated third year (20). We 95 
now report immunological findings from this trial, including peripheral blood cellular and 96 
humoral assessments, as well as local tissue responses to allergen: evaluation of antigen-specific 97 
CD4+ T cells in peripheral blood, functional outcomes from changes in the humoral response 98 
detected in serum and peripheral IgE-dependent basophil assays and cytokine responses to 99 
allergen challenge in the nasal mucosa.  100 
  101 
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Methods 102 
Sample collection 103 
Clinical characteristics of the subjects in the GRASS study and details of the protocol 104 
have been previously reported (20). Subcutaneous alum-adsorbed grass pollen immunotherapy 105 
(Alutard SQ Grass Pollen®, ALK, Horsholm, Denmark) or matched placebo subcutaneous 106 
injections were given weekly for 15 weeks followed by monthly maintenance injections until 2 107 
years. Freeze-dried grass pollen (Phleum Pratense) sublingual tablets (Grazax®, ALK, 108 
Horsholm, Denmark) or matched placebo sublingual tablets were self-administered daily for 2 109 
years. Timothy grass-specific IgE and specific IgG4 were quantified using the CAP FEIA system 110 
(Phadia, Uppsala, Sweden). Peripheral blood lymphocytes were collected and prepared for 111 
cryopreservation as previously described (20). Coded samples were provided to the operator. 112 
Tetramer assays and flow cytometry analysis 113 
Timothy grass specific CD4+ T cell epitopes were identified by Tetramer Guided Epitope 114 
Mapping (21, 22). Epitope specific pMHC tetramer reagents were generated by loading specific 115 
peptides onto biotinylated soluble DR monomers, and subsequently conjugated with PE-116 
streptavidin (23). These included HLA-DR04:01, DR03:01, DR04:01, DR07:01, DR10:01 and 117 
DR11:01 tetramer reagents. For ex vivo tetramer staining, 20 to 40 million frozen PBMC from 118 
subjects with HLA genotypes corresponding to these tetramers were thawed and re-suspended in 119 
200 µl of T cell culture medium and, in order to enhance tetramer staining, were treated with 120 
dasatinib (Sigma-Aldrich) for 10 minutes at 37°C before tetramer staining (24). PE-labeled, 121 
pooled tetramers were then added to a final concentration of 20 µg/ml, and the staining was 122 
carried out for 100 minutes at room temperature. 1/100 fraction of the cells were saved and the 123 
rest of the PE-tetramer positive cells were then enriched by the anti-PE bead enrichment protocol 124 
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through a magnetic column according to the manufacturer’s protocol (Miltenyi Biotec) (22, 25). 125 
Cells in both the enriched fraction and the pre-column fraction were stained with a panel of 126 
antibodies of interest, including CD14 (HCD14, Biolegend), CD19 (HIB19, Biolegend), 127 
CD45RA (HI100, BD Biosciences), CD4 (RPA-T4, BD Biosciences), CRTH2 (CRTH2, BM16, 128 
BD Biosciences), CD161 (PK136, Biolegend) and CD27 (O323, Biolegend); and were further 129 
treated with BD Via-ProbesTM (BD Biosciences), before flow cytometry. Frequencies of tetramer 130 
positive cells were calculated by the formula n/N, where n is the number of tetramer positive 131 
cells in the enriched fraction, and N is the total number of cells in the sample, which can be 132 
calculated by counting the number of cells in the pre-column fraction x 100.  Efficiency of 133 
recovery was optimized by using less than 30 million cells as starting material on samples with 134 
less than 300 tetramer-positive cells per million, capturing greater than 95% of the PE-tetramer-135 
stained populations. 136 
Isolation of grass pollen allergen-reactive T cells with CD154 upregulation assay 137 
Global grass pollen-reactive CD4+ T cells were tracked using the CD154 assay (26, 27). 138 
Briefly, frozen/thawed PBMC were cultured at a density of 106/ml with 1 µl/ml Timothy grass 139 
pollen crude extract and 1 µg/ml of anti-CD40 blocking mAb (HB14, Miltenyi Biotec). After 18 140 
hour stimulation at 37°C, cells were harvested and labeled with PE-Conjugated anti-CD154 mAb 141 
for 10 minutes at 4°C. Cells were then washed, labeled with anti-PE magnetic beads and 142 
enriched by using a magnetic column, according to the manufacturer’s instructions (Miltenyi 143 
Biotec). Magnetically enriched cells were next stained with antibodies against markers of interest 144 
and analyzed on a FACSAria™ II flow cytometer (BD). Live memory CD45RO+ CD154+ 145 
CD4+ T cells were sort-purified for subsequent transcript analysis. 146 
Real-time PCR expression analysis 147 
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The Fluidigm BioMark 96.96 Dynamic Array (28) was used to measure the gene 148 
expression in small cell populations. Ten cells per well were sorted by FACS in quadruplicate 149 
into 96-well plates containing a reaction mix for reverse transcription (CellsDirect One-Step 150 
qRT-PCR kit; Invitrogen) and pre-amplification with 96 selected gene primer pairs (DELTAgene 151 
assays, Fluidigm). After sorting, samples were reverse-transcribed and pre-amplified for 18 152 
cycles. Primers and dNTPs were removed by incubation with ExonucleaseI (NE Biolabs), and 153 
samples were diluted (5×) with TE buffer and stored at −20°C. Samples and assays (primer 154 
pairs) were prepared for loading onto 96.96 Fluidigm Dynamic arrays according to the 155 
manufacturer’s recommendations. The 96.96 Fluidigm Dynamic Arrays (Fluidigm Corp.) were 156 
primed and loaded on an IFC Controller HX (Fluidigm Corp.) and real-time PCR was run on a 157 
BiomarkHD (Fluidigm Corp.). Data were collected and analyzed using Fluidigm Real-Time PCR 158 
Analysis software (v4.1.2). 159 
Measurement of nasal cytokines 160 
Nasal challenge was performed using Aquagen® (ALK) Phleum Pratense (Timothy 161 
grass) extract as described previously (20). Challenge dose was determined according to a dose-162 
titration challenge at screening. The same dose was then used at the baseline (pre-treatment) 163 
nasal challenge visit and at each subsequent challenge visit. Dose range was 1,500 BU/ml 164 
(equivalent to 1.0 µg/ml major allergen) to 30,000 BU/ml (equivalent to 20.2 µg/ml major 165 
allergen).   166 
Nasal secretions were collected using synthetic polyurethane sponges pre-cut to 20 x 15 x 167 
15 mm (RG 27 grau; Gummi-Welz GmbH & Co., Neu-Ulm, Germany) and sterilized by 168 
autoclaving. A single sponge was inserted into each of the participant’s nostrils, posterior to the 169 
muco-cutaneous junction, by a study physician under direct vision using croc forceps and a nasal 170 
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speculum (Phoenix Surgical Instruments Ltd, Hertfordshire, UK). Sponges were left in place for 171 
2 minutes before removal and then added to 2-ml centrifuge tubes with indwelling 0.22 µm 172 
cellulose acetate filters (Costar Spin-X; Corning, Corning, NY, USA). Tubes were kept briefly 173 
on ice before being centrifuged. At baseline, sponges were centrifuged ‘neat’ without adding an 174 
elution buffer. At years 2 and 3, 75 µl of elution buffer [Milliplex Assay Buffer; Millipore, 175 
Darmstadt, Germany; PBS pH 7.4, BSA (1%), Tween-20 (0.05%), sodium azide (0.05%)] was 176 
added to sponges within their centrifuge tubes before being centrifuged. The isolated fluid was 177 
then pipetted into Eppendorf tubes and stored at -80°C.  178 
After thawing, nasal fluid was analyzed for cytokines in yearly batches. Measurements of 179 
IL-4, IL-5, IL-10, IL-13 and IFN-γ, were performed using MSD Human TH1/TH2 7-Plex, Ultra-180 
Sensitive Kit according to the manufacturer's instructions (MS6000 7 spot; Meso Scale 181 
Discovery, Maryland, USA). Briefly, after incubation of plates with diluent, 25 µl of samples, 182 
calibrators, and high and low standards were added to appropriate wells and incubated on a plate-183 
shaker for 2 hours. Plates were then washed in PBS plus 0.05% Tween-20 using an automated 184 
washer (Aquamax 2000). Twenty-five microliters of detection antibody at 1µg/ml was added to 185 
wells, followed by incubation on a plate-shaker for 2 hours in the dark. Plates were then washed 186 
3 times as before. One hundred and fifty microliters of Read Buffer T were then added to each 187 
well before plates were read on an MSD SECTOR® 6000 instrument. All measurements were 188 
performed in duplicate and reported as mean values per standardized volume. The assay was 189 
validated for analysis of nasal secretion and the level of quantification was 5-5000 pg/ml for all 190 
cytokines. 191 
IgE-FAB and basophil activation 192 
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Serum inhibitory activity for IgE-facilitated allergen binding and presentation was 193 
measured by FAB assay (10, 29, 30). Briefly, an indicator serum containing high concentration 194 
of Timothy grass pollen (P. pratense)-specific IgE (>100 IU/mL), was pre-incubated with 1 195 
µg/mL allergen at 37°C for 1 hour to allow formation of allergen-IgE complexes. To test for 196 
inhibition of facilitated allergen binding, indicator serum and test serum (baseline, year 1, year 2 197 
and year 3) or RPMI alone as a control was mixed. During this step, CD23-enriched EBV- 198 
transformed B cells were washed three times by centrifugation in RPMI-1640 at 423 x g for 7 199 
minutes at 4°C. Cells were then re-suspended in FAB buffer (138.60 mM NaCL, 1.12 mM 200 
NaH2PO4, 8.16 mM Na2HPO4 and 0.1% bovine serum albumin dissolved in 1 liter of distilled 201 
H2O, adjusted pH to 7.2) at 2x107 cells/ml. 1×105 EBV-transformed B cells were added to the 202 
IgE serum/allergen complexes and incubated for 1 hour at 4°C on ice. Cells were then washed 203 
twice to remove any unbound allergen-IgE complexes and immunostained with PE-labelled anti-204 
human IgE (Miltenyi; Biotech, Woking, UK) for 45 minutes at 4°C on ice. The cells were then 205 
washed and re-suspended in FAB buffer and the percentage of cells bound by allergen-IgE 206 
complexes was assessed by flow cytometry (BD FACSCanto II; BD Biosciences, San Jose, CA) 207 
and data analyzed with FACS DIVA software (BD Biosciences, San Jose, CA). Five thousand 208 
gated cells were analyzed and all samples were measured in triplicate.  209 
Assessment of ex-vivo allergen-induced basophil responsiveness by flow cytometry was 210 
performed on heparinized whole blood (47). Briefly, whole blood was incubated with or without 211 
100 ng/ml of P. pratense extract (ALK-Abelló) in a 37°C water bath for 15 minutes. Cells were 212 
immunostained with anti-human CD3, CD303, CD294 (CRTh2), CD63 (all BD Biosciences, San 213 
Jose, CA). Erythrocytes from whole blood were lysed with BD lysing solution (BD Biosciences, 214 
San Jose, CA) for 10 minutes at room temperature in the dark, samples were centrifuged (5 min, 215 
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200 x g) and the supernatants discarded. The resulting cell pellets were washed in 3 ml PBS 216 
(without Ca2+ and Mg2+) and re-suspended in 450 µl ice-cold fixative solution (CellFix, BD 217 
Biosciences, San Jose, CA) prior to acquisition on the BD FACSCanto II flow cytometer (BD 218 
Biosciences, San Jose, CA). Activated cells were also identified as CD63+CRTh2+ basophils. 219 
Analyses were performed using FlowJo v10.2 (FlowJo, LLC, Oregon). 220 
Statistics 221 
In the GRASS trial, the intention to treat population included 106 randomized 222 
participants of whom 92provided an evaluable primary endpoint at 3 years. (20). The per-223 
protocol (PP) population included 84 participants who remained in the study 3 years, were 224 
compliant with study medications, defined as taking 50% or more of their study medication for 225 
the duration of the study, and had an evaluable primary endpoint. All mechanistic data were 226 
assessed in the PP population using a linear mixed model adjusted for baseline values. To be 227 
consistent, clinical endpoints, nasal challenge induced total nasal symptom score (TNSS) area 228 
under curve (AUC) and peak nasal inspiratory flow (PNIF) change from pre-challenge AUC, 229 
were re-analyzed in the PP population using a linear mixed model adjusted for baseline values. 230 
The threshold for significance was p<0.05 (two-sided). Since all analyses were considered 231 
exploratory, p-values were not adjusted for multiple comparisons. Analyses were performed with 232 
SAS Version 9.4 (SAS Institute Inc., Cary, NC) and R version 3.2.4 (R Foundation for Statistical 233 
Computing). 234 
Data and materials availability  235 
Datasets and Figures from this study, along with clinical data from the GRASS trial, are 236 
available on TrialShare, the Immune Tolerance Network data visualization portal, at:  237 
https://www.itntrialshare.org/GRASSmech.url. 238 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
Study approval 239 
Written informed consent was received from participants prior to inclusion in the study. 240 
The study was approved by the National Research Ethics Committee in the UK. 241 
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Results  242 
Peripheral antigen-specific T cells 243 
Allergen-specific T cell responses were assessed by direct ex vivo HLA class II tetramer 244 
staining of CD4+ lymphocytes from peripheral blood. Peptide epitopes from the major Timothy 245 
grass pollen allergens Phl p 1 and Phl p 5 that were used for tetramer production are shown in 246 
Table I; HLA genotypes in the Table were matched for each subject analyzed. Figure 1 shows 247 
representative flow cytometry analysis of these allergen-specific T cells from a study participant 248 
receiving subcutaneous grass allergen immunotherapy. Detection of lymphocytes that bind the 249 
tetramers—consisting of timothy grass peptides bound to HLA class II molecules—identifies 250 
CD4 T cells specific for the grass pollen allergen. As shown in Figure 1A, flow cytometry 251 
profiles prior to therapy identify grass pollen-specific T cells in peripheral blood that display a 252 
typical allergic profile, with expression of CRTH2, CD161 and CCR4 surface markers 253 
characteristic of Th2 lymphocytes involved in allergic diseases, and few cells expressing CD27. 254 
Two years after continuous subcutaneous immunotherapy (SCIT), profiles of remaining allergen-255 
specific T cells have shifted as characterized by reduced frequencies of the 256 
CCR4/CRTH2/CD161-positive cells, and increased frequencies of CD27-positive cells. This 257 
altered pattern of cell-surface markers indicates a phenotypic change consistent with a loss of 258 
Th2 cells in the circulating allergen-specific compartment. However, after one additional year off 259 
therapy, this phenotypic profile has reverted back towards the original distribution of allergic 260 
markers, once again displaying increased frequencies of CRTH2- and CD161-positive cells and 261 
reduced frequency of CD27-positive cells in the allergen-specific CD4 T cell compartment. 262 
Figure 1B summarizes these profiles for 53/84 Per Protocol population (SCIT: 16, SLIT: 263 
21, placebo: 16) enrolled in the GRASS clinical trial in whom there was adequate HLA-264 
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matching for tetramer-profiling of allergen-specific T cells. In placebo-treated participants, 265 
allergen-specific CD4 T cell frequencies were stable over 3 years. Participants in both the 266 
subcutaneous and the sublingual therapy arms of the trial showed significant decreases compared 267 
to placebo in the frequencies of allergen-specific cells, during the first year of treatment, a 268 
timepoint where clinical parameters in the two arms were also similar (Fig 1C). This downward 269 
trend continued in the group receiving a 2nd year of subcutaneous therapy and remained 270 
significant compared to placebo, while the decline appeared to plateau in the sublingual group 271 
compared to placebo at year 2 (Fig. 1B) The decrease in overall CD4 antigen-specific cells (Fig. 272 
1B [left panel]) reflects the specific decrease in Th2 cells (Fig. 1B [right panel]). After two years 273 
of therapy, subjects receiving subcutaneous therapy had fewer allergen-specific Th2 cells in the 274 
peripheral blood compared to the sublingual therapy group. Notably, one year after 275 
discontinuation of the allergen therapy, specific CD4 T cell numbers in both treatment groups 276 
returned to the baseline frequencies, indicating a lack of a durable immunological effect. 277 
These antigen-specific T cell profiles are remarkably concordant with the clinical 278 
parameters measured in the GRASS trial (20). This is illustrated in Figure 1C for symptom-279 
related outcomes of the per-protocol subjects studied in the trial, with clinical outcomes 280 
measured on the same day as collection of samples used for the T cell analysis: the total nasal 281 
symptom score (TNSS), a composite clinical index (scale 0-12) of the severity of nasal 282 
symptoms after nasal allergen challenge (left panel), and the peak nasal inspiratory flow (PNIF), 283 
an objective measurement of nasal airflow obstruction (right panel), for the same subjects and 284 
time-points. Clinical improvement was seen with both forms of immunotherapy over the two 285 
year period of treatment, but reverted back to the baseline allergic parameters at year 3, one year 286 
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after discontinuation of treatment. Thus, the allergen-specific CD4+ T cell frequencies measured 287 
by flow cytometry of tetramer-binding cells closely paralleled clinical outcomes. 288 
Effects of therapy on local Th2 cytokines 289 
Nasal allergen challenges were performed before treatment and at yearly intervals, with 290 
collection and cytokine analysis of nasal fluids. Nasal allergen challenge-induced increases in 291 
interleukin (IL)-4, IL-5 and IL-13 in nasal fluids were significantly suppressed after 2 years 292 
treatment with either subcutaneous or sublingual immunotherapy, as shown in Figure 2. There 293 
was no treatment effect on IFN-γ or IL-10 responses, indicating that both treatment modalities 294 
selectively reduced local Th2 cytokines. Similar to what we observed with allergen specific Th2 295 
cells in peripheral blood, and in parallel with clinical outcomes in Figure 1C, suppression of 296 
these local Th2 cytokine responses to nasal allergen provocation was not maintained one year 297 
after therapy cessation at year 3.    298 
These changes in mucosal cytokines together with fewer circulating allergen-specific Th2 299 
cells, suggested an overall decrease of Th2 immunity in desensitized subjects. We confirmed this 300 
interpretation through transcriptional analysis of antigen-reactive memory CD4+ T cells at 301 
baseline and at year 2 (Supplemental Figure 1A) (27, 31). For these experiments, cryopreserved 302 
PBMC were stimulated with Timothy grass extract overnight in the presence of anti-CD40, and 303 
upregulation of CD154 on memory CD4+ T cells was used to identify allergen-reactive T cells. 304 
Similar to the tetramer assay, both subcutaneous and sublingual treatment modalities reduced the 305 
frequency of allergen-reactive memory CD4+ T cells in peripheral blood at year 2, but this 306 
reduction was only statistically significant for subcutaneous immunotherapy. These CD154-307 
positive cells were isolated using fluorescence-activated cell sorting and RNA extracted for 308 
transcriptional analysis; as shown in Supplemental Figure 1B. The CD27-negative population of 309 
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allergen-reactive cells displayed a characteristic Th2 transcript profile with increased IL-4, IL-5, 310 
IL-13, IL-31 and ST2 expression, consistent with a Th2-predominant phenotype of the allergen-311 
specific CD4+ T cells impacted by specific immunotherapy. 312 
Humoral immunological outcomes 313 
As previously reported, Timothy grass pollen-specific IgG4 levels increased during 314 
allergen immunotherapy, in parallel with the therapeutic response (9, 10). In order to assess the 315 
functional capacity of this induced IgG, we measured the ability of post-immunotherapy serum 316 
to inhibit the binding of allergen-IgE complexes to B cells (IgE-FAB), an in vitro surrogate of 317 
IgE-facilitated antigen presentation. In this assay, serum from patients who have received 318 
allergen-specific immunotherapy was evaluated for its ability to inhibit this allergen-IgE 319 
complex binding (10). As shown in Figure 3A, there was a marked decrease in IgE-FAB during 320 
allergen immunotherapy, for both subcutaneous and sublingual-treated subjects. Interestingly, 321 
after 2 years therapy, the changes in allergen specific IgG4/IgE ratios were 10-fold higher after 322 
subcutaneous compared to sublingual immunotherapy (Fig. 3B), whereas the changes in IgG-323 
associated inhibitory activity for IgE-FAB were comparable for the 2 groups. At 3 year follow 324 
up, one year off therapy, the IgE-FAB binding trended back towards baseline values, but 325 
remained significantly depressed relative to placebo-treated participants. This pattern was similar 326 
to the profile reflected in the allergen-specific IgG4-to-IgE ratio (Fig. 3B). 327 
Basophil activation is another indicator of IgE-mediated allergic response that can be 328 
monitored ex vivo by detection of basophil surface activation markers following incubation of 329 
grass pollen allergen with whole blood (32, 33). Similar to what was observed for serum 330 
inhibitory activity for IgE, both therapies significantly suppressed grass pollen allergen-induced 331 
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basophil hyper-responsiveness as measured by surface CD63 expression. This effect persisted at 332 
year 3 follow up, one year after withdrawal of treatment (Fig. 3C). 333 
Relationships between local tissue and systemic immunological parameters 334 
The overall concordance between decreased nasal Th2 cytokine measurements, lower 335 
peripheral blood antigen-specific CD4+ T cells, and antigen-specific IgE activity after 2 years of 336 
allergen desensitization therapy suggested coordinated immune mechanisms. To explore the 337 
relationship between the treatment effect on these immunological parameters, each was plotted 338 
for individual subjects as year 2 fold-change from baseline in a 3-D scatter plot. Indeed, we 339 
identified a distinct co-clustering of study participants within the immunotherapy treatment arms, 340 
well-demarcated from the placebo-treated controls (Fig. 4). Many participants cluster near the 341 
origin of the graph, indicating synchronous allergen-specific CD4+ T cell, nasal Th2 cytokine, 342 
and antibody changes, suggesting that the changes observed are reflecting the same shift in the 343 
immune responses even though differences in the significance compared to placebo are 344 
observed. There was no difference between the subcutaneous and sublingual treatment groups, 345 
which cluster together in this analysis at the end of two years of desensitization therapy.  346 
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Discussion  348 
Allergic manifestations are largely driven by Th2-mediated immune mechanisms, and 349 
allergen-specific immunotherapy may inhibit, deviate and/or delete these effector responses. In 350 
the GRASS clinical trial, immunological assays were utilized to directly compare different 351 
immune modalities, monitoring subjects using a highly sensitive and specific tetramer assay to 352 
identify and phenotype allergen-specific CD4+ T cells, a sensitive and quantitative measurement 353 
of in vivo, allergen-provoked nasal cytokines to measure local mucosal immunity, and two 354 
assessments of peripheral allergen-specific IgE reactivity, namely inhibitory activity for IgE-355 
FAB and inhibition of allergen-stimulated peripheral basophil activation. The distinctive 356 
opportunity to conduct this study in the context of a randomized, placebo-controlled trial 357 
comparing two different forms of allergen administration in humans is unique, as is the 358 
integration of immunobiology for antigen-specific peripheral blood T cells and humoral 359 
immunity with in vivo target organ immune response following allergen exposure.  360 
The three modalities tested—specific T cells, local cytokines, and specific humoral 361 
immunity—were generally concordant while on treatment, as demonstrated by the movement 362 
toward the origin of both subcutaneous and sublingual treated populations in Figure 4. Thus, 363 
despite the fundamentally different routes of allergen administration and treatment between 364 
sublingual and subcutaneous therapy, with corresponding site-specific differences in antigen 365 
presentation, allergen immunotherapy via either route of exposure similarly reduced the 366 
immunological effectors of the allergic response in each case. However, differences were evident 367 
in the magnitude, timing and duration of effect: Allergen-specific CD4+ T cells were decreased 368 
in frequency after one year of treatment via either the subcutaneous or sublingual route, and 369 
continued to decrease during therapy for a second year only in subjects receiving subcutaneous 370 
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allergen immunotherapy. This decrease occurred within the Th2 subpopulation of allergen-371 
specific memory T cells, characterized by expression of CRTH2 and CD161, and lack of 372 
expression of CD27 (22). Transcript analysis of allergen-reactive CD4+ T cells, purified using 373 
the parameter of CD154-upregulation after allergen exposure in vitro, confirmed the loss of Th2 374 
phenotype (Supplemental Figure 1). Similar kinetics were found in the serum immunoglobulin 375 
compartment: Therapeutic elevations of the ratio of specific IgG4/IgE, as well as decreases in 376 
facilitated IgE binding assays were seen with both forms of specific immunotherapy, but were 377 
more prominent earlier—at one year after initiation of therapy—in the subcutaneous treatment 378 
arm. 379 
Clinical symptoms improved in the GRASS study participants during therapy, but this 380 
response was not durable. When assessed one year after discontinuation of treatment, subjects 381 
receiving either form of immunotherapy regained their responses to allergen challenge, 382 
indicating a lack of immune tolerance (20). Of the three types of immunological characteristics 383 
studied—circulating T cells, local tissue cytokines and systemic immunoglobulins—the allergen-384 
specific CD4+ T cell frequencies and nasal Th2 cytokine levels showed a close temporal 385 
relationship with clinical outcome, reverting back to baseline values after cessation of therapy at 386 
year three. This supports the concept that future clinical studies for allergen tolerance may need 387 
to focus on more durable strategies for deleting or deviating the allergen-specific T cell 388 
compartment; an example is the current CATNIP clinical trial (NCT 02237196) combining anti-389 
TSLP with allergen-specific immunotherapy. 390 
IgG4/IgE and functional assays of IgE-FAB and basophil activation showed a slightly 391 
different pattern compared to the T cell responses (Fig. 3). Increases in specific IgG4/IgE ratio 392 
and inhibition of IgE-FAB (which is known to be largely IgG4-associated (34)) were less marked 393 
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for sublingual compared to subcutaneous immunotherapy at year 1. In contrast to the T cell 394 
response, changes in IgG4/IgE-blocking activity in the intervention groups persisted until year 3, 395 
one year after discontinuation, although the magnitude was reduced compared to the year 2 396 
values. This could simply reflect a slower change in immunoglobulin levels compared to the T 397 
cell profiles over time, or alternatively might indicate the potential for uncoupling of B cell 398 
associated responses—raising the possibility that B cells might be more amenable to long-term 399 
tolerance effects of specific immunotherapy.  400 
Previous studies of allergen-responsive T cells during immunotherapy have revealed 401 
immune deviation away from Th2 in favor of Th1 responses (35, 36) whereas others have shown 402 
no change in T cell phenotype (37, 38). PBMCs harvested during immunotherapy have shown 403 
suppression of allergen-stimulated proliferation, accompanied by increases in TGF-beta (39, 40) 404 
and/or IL-10 (39, 41-43) in culture supernatants or by ELIspot assay (44). These changes were 405 
accompanied by increases in phenotypic Tregs as determined by flow cytometry (36, 39-41). In 406 
two studies, immunotherapy-induced suppression of allergen-stimulated T cell proliferation was 407 
reversed by the addition of either anti-IL-10 (36) or TGF-beta soluble receptor (40) to the 408 
cultures. Suppression of allergen-reactive Th2 cells by measurement of allergen-stimulated 409 
CD154+ CD4+ T cells has previously been shown during subcutaneous immunotherapy (45), 410 
whereas studies of class II tetramer-positive T cells have been variable, with trials suggesting 411 
either decreases (22, 46, 47) or no change (48) in tetramer-positive cells after immunotherapy. 412 
The present study demonstrates clear decreases in tetramer-positive phenotypic Th2 cells that 413 
parallel the clinical response during and following specific immunotherapy, similar for both 414 
subcutaneous and sublingual modes of allergen administration. 415 
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Transient increases in specific IgE and IgG4/IgE ratios have previously been 416 
demonstrated (9, 10) but not in a long-term comparison of sublingual and subcutaneous 417 
immunotherapy (20). In this study, while the onset of blocking antibody activity was slower for 418 
sublingual immunotherapy, it persisted at 3 years follow up and was equivalent to that observed 419 
for subcutaneous immunotherapy despite a 10-fold lower increase in specific IgG4/IgE ratio for 420 
sublingual immunotherapy after two years desensitization (Figure 3). This highlights likely 421 
differences between the two routes of delivery where local antigen processing via the sublingual 422 
route may possibly result in fewer IgG4 antibodies but with higher avidity and/or affinity and 423 
greater IgE-blocking activity. 424 
The transient clinical benefit from two years of immunotherapy in the GRASS study 425 
stands in contrast to previous allergy clinical trials (49, 50) that demonstrated more durable 426 
benefit from three years of treatment, suggesting that 3 years of desensitization may be required 427 
for sustained effects. Our finding of a close temporal relationship between the frequency of 428 
allergen-specific circulating Th2 cells and this transient clinical outcome could represent a causal 429 
relationship, in that recurrence of the T cell ‘drivers’ of allergic immunity may have abrogated 430 
the potential for durable tolerance. On the other hand, persistence of IgE-blocking antibody (9, 431 
20) may be an early indicator of a pro-tolerogenic mechanism. If this hypothesis is correct, then 432 
future strategies for allergen immunotherapy could be directed both at enhancing persistent 433 
depletion of the allergen-specific Th2 cell population for optimal induction of tolerance and 434 
augmenting the antigen-specific therapeutic B cell response for maintenance of long-term effect.  435 
  436 
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Figures 601 
Fig. 1. Analysis of allergen-specific CD4 T cells and relationship to the clinical parameters 602 
measured during the GRASS trial. (A) Representative flow cytometry analysis of 603 
tetramer bound allergen-specific T cells from a study subject receiving subcutaneous 604 
allergen immunotherapy. Lymphocytes that bind the pooled tetramers are displayed on 605 
the y axis and expression of phenotypic cell surface markers CD4, CRTH2, CD27, 606 
CD161 and CCR4 are displayed on the x axis at baseline, at 2 years after continuous 607 
SCIT therapy and at 3 years after one year off therapy. (B) Frequencies of allergen-608 
specific CD4 T cells were determined for 53 HLA-DR4 subjects in the GRASS trial, by 609 
tetramer binding (left panel). Frequencies of Th2 cells are identified by 610 
CD161+CRTH2+CD27-CCR4+T4+/CD45RA-T4+ phenotypic marker expression (right 611 
panel). (C) The total nasal symptom score (TNSS) average AUC (left panel) and the peak 612 
nasal inspiratory flow (PNIF) average AUC (right panel) for 0-10 hours following 613 
allergen challenge were measured at baseline and years 1-3 for all participants treated 614 
with sublingual immunotherapy (green), subcutaneous immunotherapy (red), and placebo 615 
(blue). Significant differences are indicated by * (p<.05), ** (p<.01). Data are shown as 616 
means with 95% confidence intervals, for the 84 per-protocol subjects enrolled in the 617 
GRASS trial. 618 
 619 
Fig. 2. Cytokine levels of nasal fluids following nasal allergen challenge. The levels of cytokines 620 
IL-4, IL-5 and IL-13 in nasal fluids for 10 hours following nasal allergen challenge are 621 
displayed from study subjects at baseline, after 2 years of desensitization and at 3 years, 622 
one year after discontinuation of desensitization therapy. Participants treated with 623 
sublingual immunotherapy are displayed in green, subcutaneous immunotherapy in red 624 
and placebo in blue. Data are shown as means with 95% confidence intervals. 625 
626 
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Fig. 3. Allergen-specific IgE-dependent functional assays. (A) The impact of the IgG4 increase on the ability of 627 
allergen-IgE complexes to bind B cells was measured by IgE-FAB assay. The serum from patients was evaluated for 628 
ability to inhibit allergen-IgE complex binding at baseline and years 1-3. (B) Grass pollen-specific IgG4 and IgE 629 
were monitored and the IgG4/IgE ratio is displayed for subjects at baseline, after years 1 and 2 during 630 
desensitization therapy and at 3 years after discontinuation of therapy. (C) Basophil surface activation markers from 631 
whole blood of participants treated with sublingual immunotherapy (green), subcutaneous immunotherapy (red) and 632 
placebo (blue) at baseline and years 1-3 after incubation with grass pollen allergen. Significant differences are 633 
indicated by * (p<.05), ** (p<.01). Data are shown as means with 95% confidence intervals. 634 
 635 
Fig. 4. Relationship between nasal cytokine measurements and lower peripheral blood antigen-specific T cells 636 
(memory tetramer + cells) and serum antigen-specific IgE-FAB for each individual studied. Data displayed are 637 
expressed as fold changes from the baseline at year 2 (on treatment) for each immunological parameter measured for 638 
participants treated with Sublingual immunotherapy (green diamonds), Subcutaneous immunotherapy (red 639 
triangles), and placebo (blue circles), so values <1 on each axis represent reduction (improvement) in the parameters 640 
shown. Nasal cytokine measurements are the summation of area under curve (AUC) from 2 to 10 hours post-641 
challenge for Th2 cytokines (IL-4, IL-5 and IL-13). Lower peripheral blood antigen-specific T cells are measured as 642 
the frequency of memory tetramer + cells per million CD4+ cells. Serum antigen-specific IgE-FAB is measured as 643 
the percentage of allergen-IgE binding to B cells. Cluster distributions were compared using a Hotelling T-square 644 
test, as follows: Placebo vs. SCIT: p<0.001; Placebo vs. SLIT: p<0.001; SLIT vs. SCIT: p=0.31. An online 645 
interactive version of this Figure is available at https://www.itntrialshare.org/GRASSmech_fig4.url. 646 
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Table I.  648 
Peptide epitopes from the major grass allergens used for HLA class II tetramer production.  649 
HLA Class II tetramers AA sequences 
DRB1*0101 Phl p 1 153-172 KGSNPNYLALLVKYVNGDGD 
 Phl p 5b 26-45 KLIEDINVGFKAAVAAAASV 
   
DRB1*0301 Phl p 1 169-188 GDGDVVAVDIKEKGKDKWIE 
   
DRB1*0401 Phl p 1 97-116 EEPIAPYHFDLSGHAFGAMA 
 Phl p 1 221-240 TEAEDVIPEGWKADTSYESK 
   
DRB1*0701 Phl p5a 119-138 PEAKYDAYVATLSEALRIIA 
 Phl p5b 90-109 ATPEAKFDSFVASLTEALRV 
   
DRB1*1001 Phl p5a 32-51 GKATTEEQKLIEKINAGFKA 
 Phl p5a 103-122 LDAAYKLAYKTAEGATPEAK 
 Phl p5a 167-186 VDAAFKVAATAANAAPANDK 
   
DRB1*1101 Phl p 1 153-172 KGSNPNYLALLVKYVNGDGD 
 Phl p 1 185-204 KWIELKESWGAIWRIDTPDK 
 Phl p5a 79-98 FAEGLSGEPKGAAESSSKAA 
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Supplementary Materials:                Supplemental Figure 1 651 
Fig. S1. Antigen reactive memory CD4+ T cells and mRNA expression profiles. (A) 652 
Frequency of antigen reactive cells after 2 years of desensitization treatment based on CD154 up-653 
regulation after allergen stimulation. Participants treated with sublingual immunotherapy are 654 
displayed in green, subcutaneous immunotherapy in red and placebo in blue. An Analysis of 655 
Covariance (ANCOVA) model with baseline adjustment was used for analyzing CD154 assay 656 
data. Data are shown in the plot as means of log10 fold change from baseline with 95% 657 
confidence intervals. 658 
 (B)  Transcriptional analysis of extracted RNA from CD27+CD154+ and CD27- CD154+ cells 659 
at the 2-year timepoint. Transcript levels are displayed in color scale from high (yellow) to low 660 
(blue). Genes are grouped by category with Th2 in red, apoptosis in grey and Th1 related genes 661 
in purple.   662 
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Supplementary Materials:                Supplemental Figure 1 1 
Fig. S1. Antigen reactive memory CD4+ T cells and mRNA expression profiles. (A) 2 
Frequency of antigen reactive cells after 2 years of desensitization treatment based on CD154 up-3 
regulation after allergen stimulation. Participants treated with sublingual immunotherapy are 4 
displayed in green, subcutaneous immunotherapy in red and placebo in blue. An Analysis of 5 
Covariance (ANCOVA) model with baseline adjustment was used for analyzing CD154 assay 6 
data. Data are shown in the plot as means of log10 fold change from baseline with 95% 7 
confidence intervals. 8 
 (B)  Transcriptional analysis of extracted RNA from CD27+CD154+ and CD27- CD154+ cells 9 
at the 2-year timepoint. Transcript levels are displayed in color scale from high (yellow) to low 10 
(blue). Genes are grouped by category with Th2 in red, apoptosis in grey and Th1 related genes 11 
in purple.   12 
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